Papers by Sherzod Abdullaev
Kidney International Reports, 2020
Kidney International Reports, Feb 1, 2022
Počki, Jul 11, 2023
Membranous nephropathy (MN) is a heterogeneous group of diseases characterized by a common histop... more Membranous nephropathy (MN) is a heterogeneous group of diseases characterized by a common histopathological picture in the form of diffuse thickening and changes in the structure of the glomerular basement membrane (GBM) as a result of subepithelial and intramembranous deposition of immune complexes and deposition of matrix material produced by affected podocytes. Podocyte injury resulting from the immune deposits increases glomerular permeability to plasma proteins, which results in protei nuria and potentially in nephrotic syndrome (NS). In the kidneys, in situ, immune complexes are formed, consisting of their own podocyte or exogenous antigens and autoantibodies produced for them, belonging to the immunoglobulin (Ig) G class. This leads to complement activation along the classical pathway with the formation of a membrane attack complex in the subepithelial space [1, 2]. J. Feehally, in his famous book "Comprehensive Clinical Nephrology" (2016), notes that the term membranous refers to thickening of the glomerular capillary wall on light microscopy of a kidney biopsy, but the condition now called membranous nephropathy is determined using immunofluorescence and electron microscopy. These methods reveal diffuse fine-grained immune deposits on immunofluorescence and electron-dense deposits in the subepithelial
Nephrology Dialysis Transplantation, Jun 1, 2023
The interaction between phosphate and calcium in affecting all-cause mortality. (A) Thick lines r... more The interaction between phosphate and calcium in affecting all-cause mortality. (A) Thick lines represent the HR for all-cause mortality based on calcium levels for different phosphate levels (1st,50th and 99th percentile). Orange bands represent 95% confidence intervals. (B) Thick lines represent the HR for all-cause mortality based on phosphate levels for different calcium levels (1st,50th and 99th percentile). Green bands represent 95% confidence intervals. (C) Heatmap of the risk of dying (the darker the color, the higher the risk) based on calcium and phosphate levels. For all plot's, fully adjusted models were used (baseline analysis to the left and time-dependent analysis to the right). Results: In 1294 patients, the prevalence of CKD-MBD at baseline was 94%. Both PTH (aHR 1.12, 95%CI 1.03-1.23, p 0.01) and phosphate (aHR 1.35, 95%CI 1.00-1.84, p 0.05), but not calcium (aHR 1.11, 95%CI 0.57-2.17, p 0.76), were associated with all-cause mortality. Calcium was not independently associated with mortality, but modified the effect of phosphate, with the highest mortality risk found in patients with both hypercalcemia and hyperphosphatemia. PTH level was associated with CV mortality, but not with non-CV mortality, whereas phosphate was associated with both CV and non-CV mortality. Conclusion: CKD-MBD is very common in older non-dialysis patients with advanced CKD. PTH and phosphate are independently associated with allcause mortality in this population. While PTH level is only associated with CV mortality, phosphate seems to be associated with both CV and non-CV mortality.
Nephrology Dialysis Transplantation, Jun 1, 2023
Kidney International Reports, Feb 1, 2022
Nephrology Dialysis Transplantation, Jun 1, 2023
Kidney International Reports, 2021
Nephrology Dialysis Transplantation, Jun 1, 2023
Background and Aims: Antibody induction therapy is frequently used as an adjunct to the maintenan... more Background and Aims: Antibody induction therapy is frequently used as an adjunct to the maintenance immunosuppression in adult kidney transplant recipients (KTRs). There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in KTRs. The purpose of the present study was to compare induction therapy involving tocilizumab with the most commonly used induction regimens in patient populations at either high immunologic risk or low immunologic risk. Method: In this prospective study, we randomly assigned patients to receive tocilizumab or conventional induction therapy such as basiliximab. Patients were stratified according to acute rejection risk, with a high risk defined by a repeat transplant, a peak or current value of panel-reactive antibodies of 30% or more. The 102 high-risk patients received tocilizumab (one dose of 8 mg/kg, in 52 patients) or basiliximab (a total of 40 mg over 4 days, in 50 patients). The 113 low-risk patients received tocilizumab (one dose of 8 mg/kg, in 62 patients) or basiliximab (a total of 40 mg over 4 days, in 51 patients). All patients received tacrolimus and mycophenolate mofetil and underwent a 10-days glucocorticoid (prednisone) taper in a regimen of early steroid withdrawal. The primary end point was biopsy-confirmed acute rejection at 6 months and 12 months. Patients were followed for 2 years for safety and efficacy end points. Results: The rate of biopsy-confirmed acute rejection was significantly lower in the tocilizumab group than in the basiliximab group at both 6 months (5.3% vs. 10.9%, P<0.01) and 12 months (7.9% vs. 12.9%, P<0.01). At 2 years, the rate of biopsy-confirmed acute rejection in low-risk patients was lower with tocilizumab than with basiliximab (9.7% vs. 17.7%, P<0.05), but among high-risk patients, no significant difference was seen between tocilizumab and basiliximab (19.2% vs. 16.0%, P = 0.68). Adverse-event rates were similar among all four treatment groups. Conclusion: By the first year after transplantation, biopsy-confirmed acute rejection was less frequent with tocilizumab than with conventional therapy. The apparent superiority of tocilizumab with respect to early biopsy-confirmed acute rejection was restricted to patients at low risk for transplant rejection; among high-risk patients, tocilizumab and basiliximab had similar efficacy. Further randomized and controlled studies are needed to support these results.
Nephrology Dialysis Transplantation
Background and Aims Albuminuria in patients with diabetes presents a higher risk for adverse rena... more Background and Aims Albuminuria in patients with diabetes presents a higher risk for adverse renal and cardiovascular (CV) outcomes. Sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrate improved albuminuria and reduces the risk of end-stage renal disease in patients with chronic kidney disease. The study aim was the impact of the SGLT2 inhibitor dapagliflozin on urine albumin-to-creatinine ratio (UACR) and GFR decline. Method In the single center trial, total 132 participants with CKD and type 2 diabetes (T2D) were randomly assigned to dapagliflozin (n = 78) 10 mg once daily or placebo (n = 54). Kidney inclusion criteria were eGFR 30-60ml/min/1.73 m2 and any UACR. The primary end point was a composite of sustained decline in eGFR ≥50%, end-stage renal disease, or kidney or cardiovascular death. Percentage treatment difference was estimated by geometric mean ratio for the overall cohort and by eGFR and UACR subgroups. Progression/regression of UACR were assessed. Hazard rat...
Nephrology Dialysis Transplantation
Background and Aims Patients with CKD are highly vulnerable to the serious complications of sever... more Background and Aims Patients with CKD are highly vulnerable to the serious complications of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections and thus stand to benefit from vaccination. Therefore, our aim is to evaluate the effectiveness of available COVID-19 vaccines in patients with CKD. Method A total of 198 consecutive adult CKD patients in a single center in Uzbekistan were evaluated. Patients were divided into four cohorts: haemodialysis (HD) (n=116), peritoneal dialysis (PD) (n=11), kidney transplant (KT) recipients (n=22) and non-dialysis CKD (stages 4 and 5, eGFR <30 mL/min/1.73 m2) (n=49) patients (Fig. 1). All the screened participants received the complete vaccination with any of the available vaccines: Pfizer-BioNTech®, Moderna®, AstraZeneca®, Sputnik V®, ZF-UZ-VAC2001®. At baseline and on day 28 after the last vaccine dose, antibodies were measured and compared between cohorts. Factors associated with development of antibodies were analyzed. Re...
Nephrology Dialysis Transplantation
Background and Aims The comorbid conditions of atrial fibrillation (AF) and chronic kidney diseas... more Background and Aims The comorbid conditions of atrial fibrillation (AF) and chronic kidney disease (CKD) leads to an increased risk of thromboembolic complications, but on the other hand is a risk factor for various bleeding. Oral anticoagulant therapy is the standard for the prevention of thromboembolic complications in AF. But with the deterioration of kidney function, the risk of hemorrhagic complications increases dramatically. This problem makes it difficult to choose an effective and safe oral anticoagulant therapy. Clinical data on the use of new oral anticoagulants (NOACs) in patients with AF and advanced CKD are limited, which determines the relevance of conducting studies in comparison with vitamin K antagonists. The aim of study was evaluation of safety parameters for the using of rivaroxaban in patients with stage 4 CKD with AF. Method The study included 109 patients over the age of 18 with a diagnosis of stage 4 CKD (eGFR – 15–29 ml/min/1.72 m2) and non-valvular AF. The...
International Journal of Mechanics and Materials in Design
Kidney International Reports, 2022
Electronic Journal of General Medicine
Purpose: Assessment of public knowledge of chronic kidney disease (CKD) is an essential step in d... more Purpose: Assessment of public knowledge of chronic kidney disease (CKD) is an essential step in development of CKD prevention and screening programs. Our aim was to estimate the level of public CKD knowledge and its predictors in the former Soviet Union countries using a validated questionnaire. Materials and methods: This cross-sectional survey was conducted in 10 countries using an adapted validated online questionnaire. Descriptive statistics were used to describe participants’ characteristics and assess public CKD knowledge level. A multiple linear regression analysis was performed to identify predictors of CKD knowledge. Results: 2,715 participants satisfied the inclusion criteria. Respondents having higher level of education, living in countries belonging to the lower middle-income countries, having a personal history of diabetes and hypertension, and having a family history of kidney disease showed significantly better CKD knowledge. Conclusions: The level of CKD knowledge am...
Uploads
Papers by Sherzod Abdullaev